Posts by: Alejandra Viviescas, PhD

Alejandra Viviescas, PhD

Alejandra has a PhD in Genetics from São Paulo State University (UNESP) and is currently working as a scientific writer, editor, and translator. As a writer for BioNews, she is fulfilling her passion for making scientific data easily available and understandable to the general public. Aside from her work with BioNews, she also works as a language editor for non-English speaking authors and is an author of science books for kids.

November 15, 2019November 15, 2019

Aquestive Licenses ALS Therapy Riluzole Oral Film to Zambon in the European Union

News

Aquestive Therapeutics has granted a development and commercialization license to Zambon Pharma for its investigational oral film formulation of riluzole as a treatment for amyotrophic lateral sclerosis (ALS) in the European ... Read more

November 12, 2019November 12, 2019

Aural, TGen Collaborate on Trial Assessing Effects of Acupuncture on Recently Diagnosed ALS Patients

News

Aural Analytics and the Translational Genomics Research Institute (TGen) will collaborate on a new acupuncture clinical trial to assess how the treatment affects speech in people recently diagnosed with ... Read more

November 11, 2019November 11, 2019

Radicava Now Commercially Available in Canada, MTP-CA Announces

News

Radicava (edaravone), an intravenous treatment for amyotrophic lateral sclerosis (ALS), is now commercially available in Canada, Mitsubishi Tanabe Pharma Canada (MTP-CA) has announced. The treatment was approved in Canada in ... Read more

November 4, 2019

AcuraStem Advancing Second Stage of Small Molecule Development for ALS Treatment

News

AcuraStem has triggered $3 million in Phase 2 funding from its Small Business Innovation Research (SBIR) grant, which the biotechnology company will use to start the second stage of ... Read more

June 19, 2019June 19, 2019

Increased Glucose Levels Might Protect Nerve Cells in ALS, Study in Fruit Flies Shows

News

High glucose levels might compensate for the toxic effects of an accumulation of TDP-43 — a widely expressed nuclear protein that binds both DNA and RNA — and protect ... Read more

June 11, 2019June 11, 2019

AB Science’s New Masitinib Study Validated by EMA, With Expected Start Later This Year, Company Says

News

AB Science has optimized the design of a Phase 3 confirmatory study for mastinib, its oral treatment for amyotrophic lateral sclerosis (ALS), to avoid any possibility of bias. The optimized ... Read more

February 8, 2019February 8, 2019

Antibody Decreases TDP-43 Protein Accumulation Easing ALS Symptoms, Mouse Study Suggests

News

A potential therapy for amyotrophic lateral sclerosis (ALS) consisting of an antibody that reduces the abnormal accumulation of the TDP-43 protein improved cognitive and motor performance in mice, a study shows. The ... Read more

January 14, 2019January 14, 2019

Human-derived Antibody Against SOD1 Aggregates Improves ALS Symptoms in Mouse Model, Study Shows

News

A human-derived antibody that specifically binds to abnormal superoxide dismutase 1 (SOD1) improved the symptoms and delayed disease progression in a mouse model for amyotrophic lateral sclerosis (ALS), a study ... Read more

January 11, 2019January 11, 2019

Disease Progression Has Significant Effect on Quality of Life of ALS Patients, Study Says

News

In addition to symptoms of depression, disease progression is one of the strongest influences on health-related quality of life in amyotrophic lateral sclerosis (ALS) patients, a study reports. According to the study, ... Read more

Pin It on Pinterest